Learn More
Epigenetic therapy by DNA demethylating agent 5-aza-2′-deoxycytidine (5-aza 2′dC) is clinically effective in acute myeloid leukemia; however, it has shown limited results in treatment of breast(More)
Acquired resistance against doxorubicin is a major limitation in clinical treatment of breast cancer. The molecular mechanism behind the aberrant expression of genes leading to doxorubicin resistance(More)
Oxidative injury to cellular macromolecules has been suggested as a common pathway shared by multiple etiological factors for kidney cancer. Whether the chronic oxidative stress alone is sufficient(More)
  • 1